Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 11, Issue 7, Pages 789-793Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.intimp.2011.01.026
Keywords
MDSC; Autoimmunity; Autoimmune hepatitis; EAE; IBD; Nitric oxide
Categories
Funding
- NCI NIH HHS [P30 CA023108] Funding Source: Medline
- NIAID NIH HHS [R01 AI078195-03, R01 AI078195] Funding Source: Medline
Ask authors/readers for more resources
Myeloid derived suppressor cells (MDSC) were first described nearly two decades ago. Until recently, however, descriptions of MDSC populations were found almost exclusively in animal models of cancer or in cancer patients. Over the last few years, an increasing number of reports have been published describing populations of myeloid cells with MDSC-like properties in murine models of autoimmune disease. In contrast to the proposed deleterious role of MDSC in cancer - where these cells likely inhibit tumor immunity - in the context of autoimmunity, MDSC have the potential to suppress the autoimmune response, thereby limiting tissue injury. A logical corollary of this hypothesis is that a failure of endogenous MDSC to appropriately control autoimmune T cell responses in vivo may actually contribute to the pathogenesis of autoimmune disease. (c) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available